IoT and Security to Be Highlighted at Japan IT Week Autumn 2015 Next Week, Gathering 33,000 Visitors and 540 Exhibitors
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151019006776/en/
Reed Exhibition to hold Japan IT Week Autumn during October 28-30, gathering 540 exhibitors and 33,000 visitors. (Photo: Business Wire)
Shuhei Shimada, Show Director of Japan IT Week is confident about the turn out - “Being the sister edition of Japan’s largest IT show held annually in May, Japan IT Week Spring, the show will serve as a quality platform for professionals in the IT and related fields to seek the latest solutions and services for various businesses.”
This year, the show will be split into 8 exhibitions: 6th
Cloud Computing Expo Japan, 5th
Information Security Expo, 5th
Web & Digital Marketing Expo, 5th
Smartphone & Mobile Expo, 4th
Data Center Expo, 4th
Big Data Management Expo, 3rd
Direct Commerce Solutions Expo and 1st
IoT/M2M Expo allowing a large range of professionals involved in IT
business to synergistically negotiate and network.
The floor plan can be viewed online at: http://www.japan-it.jp/en/aki/doc/floorplan/
Major firms, namely IBM JAPAN, NTT HOLDINGS, KDDI, JAPAN POST, YAMATO GLOBAL EXPRESS, SONY MARKETING, NTT COMMUNICATIONS, TWITTER JAPAN, HEWLETT-PACKARD JAPAN etc. will be exhibiting. There will also be international pavilions of Canada and Korea.
With an addition of 110 exhibitors from the previous year, the show is to gather a total of 540 exhibitors and 33,000 visitors from across Japan and the world.
Reflecting the trends in IoT and information security, exhibits related to such categories have increased and also popular topics at the conference. The show will be the perfect platform to conduct face to face business and catch the latest trends in the Japanese IT market.
Trending IoT/M2M Expo to be newly launched
A new exhibition has been added to the show line-up this year - IoT/M2M Expo. The launch of the exhibition follows the success of its spring edition of Japan IT Week where the exhibition tripled in size reflecting the increasing market of IoT and M2M in Japan. For instance, by 2020 the number of devices estimated to be connected to the internet in relation to IoT is over 50 billion globally. In Japan the market is to reach around JPY 16 trillion. Addition of IoT/M2M Expo to the show line-up has contributed greatly to the overall expansion of Japan IT Week Autumn 2015 and will serve as another business platform in Japan in the second half of the year.
Information security continues to boom
With the “My Number” scheme kicking off next year, information security related services and solutions continue to be a big investment for IT in Japan. Information Security Expo has effectively expanded by around 25% and a special exhibit area for “My Number” security has also been launched within Cloud Computing Expo Japan.
IoT and Artificial Intelligence to be big topics at the Conference
38 quality conference sessions will also run parallel to the exhibitions. Hot topics will be covered such as utilisation of connected technologies and big data in Artificial Intelligence/robotics, security measures and solutions for Japan’s “My Number” scheme, next step for e-commerce business in Japan with international markets etc.
There will be a Keynote Session on October 28 by MICROSOFT JAPAN and SAP JAPAN . MICROSOFT JAPAN will share their latest global “Intelligent Cloud” case studies as solutions for the connected world. SAP JAPAN will introduce their latest global IoT solutions and discus ideal models for innovative management systems for this new digital era.
Speakers include experts from top IT related firms such as SALES FORCE.COM, FUJITSU, CYBER AGENT, SOFTBANK, KDDI, NTT DOCOMO, AMAZON DATA SERVICE JAPAN, DROPBOX JAPAN, BOX, MINISTRY OF ECONOMY TRADE & INDUSTRY of Japan, etc.
Admission free for visitors
IT related professionals are able to visit the show for free with an online pre-registration.
Japan IT Week Show Management/Reed Exhibitions Japan Ltd.
Ena Masui, +81-3-3349-8519
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom